AAN: Ropinirole appears effective against restless legs syndrome
Unregistered User
If this is not your name, click here.
Contact Us | Order Now | Journals | Bookstore | Register a colleague
 
  SEARCH  
News
Bookstore
Medline
The Web
Meetings & Congresses
Complete Doctor's Guide
 


 EXPLORE :
 news  All News
 webcasts All Webcasts
 All cases All Cases
 Meetings All Meetings & Congresses
 Medical All Medical Resources

top





New drugs / indications

English Dictionary

Medical Dictionary

Thesaurus



Warning | Privacy | Awards



 Favourite Journals 

Click here to choose your favourite journals


 Favourite Sites 

Click here to choose your favourite sites


 Languages 



  




AAN: Ropinirole appears effective against restless legs syndrome

ATLANTA, GA -- May 1, 2000 -- Emory University neurologists have found that the drug ropinirole is a safe and effective treatment for restless legs syndrome (RLS), a common but often undiagnosed neurologic disorder. An open-label study at Emory found that low doses of ropinirole resulted in moderate to large improvement in symptoms in two-thirds of patients.

Emory neurologist Alan Freeman, M.D., the study's lead author, will present the findings Monday, May 1 at the American Academy of Neurology's 52nd Annual Meeting in San Diego.

"This study suggests that low-dose ropinirole is an effective and well- tolerated treatment for RLS," Dr. Freeman said. "This is important because RLS is a common condition that may affect five to 15 percent of the population. It's a nuisance, and can seriously disrupt one's life."

Out of the 18 patients in the study, 12 showed a moderate to marked reduction, ranging from 25 to 100 percent, in RLS disability scores after four weeks on the drug. Five of the remaining patients showed minimal improvement. Patients commonly reported minor side effects, including gastrointestinal discomfort, dizziness, headache and drowsiness.

Ropinirole is a dopamine agonist that received federal approval in 1997 for the treatment of Parkinson's disease. "The dosages used in the Emory RLS study are much lower than those typically prescribed for Parkinson's disease," Dr. Freeman said. Ropinirole is sold under the brand name Requip(R) by the pharmaceutical company SmithKline Beecham.

The hallmark of the syndrome is an involuntary urge to move the legs and other extremities, often accompanied by a tingling or crawling sensation in the legs. Symptoms typically worsen during the evening, especially when lying down or attempting to fall asleep. RLS not only disturbs sleep, but also affects waking hours.

"For example, a lot of patients can't sit through a movie," Dr. Freeman said, adding that long car rides or airplane trips also can be frustrating to people with RLS. The study was supported by a research grant from SmithKline Beecham Pharmaceuticals.

Related Links: ropinirole (Requip) and SmithKline Beecham Pharmaceuticals.

E-mail this page
to a friend or colleague!
To print,
use this version




Any question regarding a medical diagnosis, treatment, referral, drug availability or pricing should be directed to either a licensed physician or to the product's manufacturer.

If you have any technical questions or other concerns about this site, feel free to contact us at webmaster@docguide.com.

All contents Copyright (c) 1995- Doctor's Guide Publishing Limited. All rights reserved.


Employment opportunities | Partnering opportunities